Sudden Sensorineural Hearing Loss with Vertigo in a Patient on Anticoagulation
A 58-year-old man presents 5 days after the acute onset of right-sided hearing loss, constant rotary vertigo, and right tinnitus. He takes warfarin for a mechanical mitral valve (INR 2.8 today). Audiometry shows right profound sensorineural hearing loss (PTA 95 dB, word recognition 0%) and normal left hearing. MRI with gadolinium shows faint enhancement of the right cochlea and vestibule but no mass in the internal auditory canal or brainstem. He asks whether he should stop the warfarin to allow a course of high-dose oral steroids, and whether the vertigo means his hearing cannot recover.
1. How do you weigh intratympanic versus systemic corticosteroid therapy in this patient, and what do you tell him about anticoagulation?
Read the worked answer
Reasoning framework:
- Severity and timing: Profound loss with 0% word recognition and 5-day delay is a poor-prognosis profile; salvage potential favors aggressive local therapy.
- Systemic risk: High-dose oral prednisone in a patient with a mechanical valve on warfarin raises INR and bleeding risk, and the evidence does not clearly favor systemic over intratympanic steroid for profound loss.
- Decision: Offer intratympanic dexamethasone as primary or first-line therapy, which delivers high cochlear concentration with negligible systemic absorption and no meaningful interaction with warfarin. Do not advise stopping warfarin; coordinate with cardiology if any systemic steroid is added, with INR monitoring.
- Counseling: Emphasize that combination (IT plus systemic) is reasonable if anticoagulation can be safely managed, but the local route alone is defensible and lower risk here. Document shared decision-making.
2. The patient asks whether the vertigo and the cochlear enhancement on MRI change prognosis or management. What is your response?
Read the worked answer
Reasoning:
- Vertigo accompanying sudden SNHL signals vestibulocochlear (labyrinthine) involvement rather than isolated cochlear disease and is associated with worse hearing recovery and higher risk of permanent vestibular deficit. It does not change the acute treatment (steroids remain first-line) but lowers expected prognosis.
- Faint cochlear/vestibular enhancement supports an inflammatory/immune labyrinthitis pattern and argues against a retrocochlear lesion; it does not mandate a change in steroid strategy but warrants follow-up MRI if recovery is poor to exclude evolving pathology.
- Counseling: Honest prognostic framing that recovery is less likely with profound loss plus vertigo, plan for repeat audiometry, consideration of vestibular rehabilitation for chronic imbalance, and hearing rehabilitation options (hearing aid/CI evaluation) if loss persists. Emphasize that treatment still offers a chance and should not be withheld.